334 results about "Proteinoid" patented technology

The invention provides an anti-human serum albumin nano antibody and application thereof, and belongs to the technical field of antibodies. The invention provides an anti-human serum albumin nano antibody HSA-32 with relatively high affinity, and the anti-human serum albumin nano antibody HSA-32 is subjected to humanized transformation, so that three obtained humanized anti-human serum albumin nano antibodies can be used for reducing the immunogenicity of the HSA-32 and improving the immunogenicity of the HSA-32; and high specificity and high affinity of combination with the human serum albumin and stability and solubility of the antibody are maintained. The anti-human serum albumin nano antibody can be used for separation, purification and detection of human serum albumin and separation and purification of polypeptide, protein or antibody drugs fused with the anti-human serum albumin nano antibody. Meanwhile, the anti-human serum albumin nano-antibody can effectively prolong the half-life period of polypeptide, protein and antibody drugs fused with the anti-human serum albumin nano-antibody, and can be used for developing long-acting polypeptide, protein or antibody drugs.

The present disclosure provides proteins useful for preventing, treating, suppressing and / or eliminating infestations and infections of plants by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods of using such proteins, formulations, polynucleotides and organisms in agriculture and other fields of endeavor.

The invention discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition of the present invention comprises an acidic secretory protein rich in cysteine, a disaccharide chain proteoglycan, and an XV-type collagen alpha1 chain. The biological material system loaded with the three types of proteins can promote angiogenesis, and can improve the tissue regeneration efficiency of bone, cartilage and skin defect areas.

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an alpha-L-iduronidase (IDUA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat MPS I.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

The invention belongs to the technical field of microorganisms, discloses a strain of pseudomonas putida and application of the strain of pseudomonas putida as fish probiotics, and particularly discloses a strain of pseudomonas putida. The invention provides a symbiotic pseudomonas putida CD separated from fish, and the strain has relatively strong fat utilization capability, can generate a plurality of beneficial extracellular metabolites, can promote metabolism of fish lipids, carbohydrates and proteins and weight gain, and also can improve the iron content and hemoglobin content in fish tissues. The pseudomonas putida strain CD disclosed by the invention has good biological safety, and has a wide development prospect in the aspect of application as fish probiotics.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

The present invention relates to recombinant binding proteins comprising an ankyrin repeat domain with binding specificity for soluble mesothelin or membrane-bound mesothelin. In addition, the invention relates to nucleic acids encoding such recombinant binding proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer in a mammal, including a human.

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.

The invention discloses a TLP1-like gene molecular marker related to cotton verticillium wilt resistance and application of the TLP1-like gene molecular marker, and belongs to the field of biotechnology application. The promoter of the TLP1 protein gene TLP1-like has two haplotypes, the promoter sequence of the haplotype 1 is SEQ ID NO.5, and the genomic sequence of the haplotype 2 is SEQ ID NO.6. The invention also discloses a method for preparing the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene. Compared with the haplotype 1, the haplotype 2 has an SV insertion of 2623 bp at a-899 bp position of an ATG upstream promoter region of a TLP1-like gene, so that the expression quantity of the TLP1-like gene is reduced. An InDel functional marker capable of remarkably distinguishing the haplotype 1 and the haplotype 2 is further developed. Compared with the haplotype 1, the haplotype 2 has a remarkable advantage in the aspect of improving the verticillium wilt resistance of the cotton, and the silent haplotype 1 cotton plant TLP1-like remarkably improves the resistance of the cotton to verticillium dahliae. The haplotype 2 has important effects and application prospects in screening cotton disease-resistant materials and cultivating cotton high-resistance varieties.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of cow milk allergen(s), specifically T cell epitopes for T cells responsive to one or more cow milk peptides or proteins comprising, consisting of, or consisting essentially of: one or more peptides or proteins selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein comprising one or more amino acid sequences selected from any one of those sequences set forth in Tables 1, 2, and 3 (SEQ ID NOS: 1 to 1081). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such protein(s) or peptide(s).

The present disclosure includes compositions and methods for detecting the presence of: a coronavirus or an immune response relevant to a coronavirus infection including T cells responsive to one or more coronavirus peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences selected from those sequences set forth in Tables 1 to 10 (SEQ ID NOS: 1 to 3522), or a subsequence, portion, homologue, variant or derivative thereof; a fusion protein; a pool of 2 or more peptides; or a polynucleotide that encodes one or more peptides or proteins, comprising, consisting of, or consisting essentially of one or more amino acid sequences set forth in Tables 1 to 10 (SEQ ID NOS: 1 to 3522), or a subsequence, portion, homologue, variant or derivative thereof. The disclosure further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

The invention belongs to the field of medical chemistry, and particularly discloses a protein tyrosine phosphatase inhibitor, such as type 2 non-receptor protein tyrosine phosphatase (PTPN2) and / or type 1 non-receptor protein tyrosine phosphatase (PTPN1) inhibitor, a pharmaceutical composition and application thereof. The invention discloses a method for treating related diseases such as cancers and metabolic diseases by using the protein tyrosine phosphatase inhibitor.

The invention relates to a rice receptor-like protein OsBIR1 coding gene and application thereof in rice stripe virus resistant rice breeding.

The present invention relates generally to novel protease activatable interleukin-2 (IL-2) polypeptides and immunoconjugates comprising (i) an IL-2 polypeptide, (ii) a masking moiety and (iii) a linker comprising a first protease cleavage site wherein the linker has a length of 20 to 45 amino acids wherein the masking moiety is covalently linked to the IL-2 polypeptide through the linker, wherein the masking moiety is capable of binding to the IL-2 polypeptide, thereby reversibly concealing the IL-2 polypeptide, where the masking moiety comprises a second protease cleavage site, where the masking moiety does not conceal the IL-2 polypeptide when cleavage is at the first protease cleavage site and / or the second protease cleavage site. The present invention also relates to polynucleotides encoding such protease activatable interleukin-2 (IL-2) polypeptides and immunoconjugates, as well as vectors and host cells comprising such polynucleotides. The invention also relates to methods for producing the protease activatable interleukin-2 (IL-2) polypeptides and immunoconjugates of the invention, and methods of using these protease activatable interleukin-2 (IL-2) polypeptides and immunoconjugates in the treatment of disease.

Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an acid alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat Pompe disease.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention relates to the technical field of plant genetic engineering, and particularly provides cloning of a GbGELP25D gene of gossypium barbadense and application of the GbGELP25D gene of gossypium barbadense. According to the invention, the GbGELP25D gene with a full length of 1092 bp is cloned from the sea island cotton variety Xinhai No. 7 for the first time, and the gene encodes a secretory lipase protein with a signal peptide and is positioned in an extracellular gap. Through bioinformatics analysis, phylogenetic classification, protein structure modeling and signal peptide function verification, it is clear that the gene belongs to a plant GELP family. Furthermore, a virus-induced gene silencing technology is utilized to prove that the silent GbGELP25D can obviously enhance the resistance of cotton to verticillium wilt, and the mechanism of the silent GbGELP25D is closely related to activation of ethylene synthesis and signal channels and induction of expression of disease-resistant related genes. The resistance gene provided by the invention enriches gene resources of cotton verticillium wilt resistance breeding, and has important theoretical significance and application value.

The invention relates generally to CD19 antibodies and antigen-binding fragments thereof, to chimeric receptors comprising the same, and to cells configured to express such proteins. The invention also relates to methods of using such antibodies, chimeric receptors, and cells in the treatment of various diseases, including cancer and autoimmune diseases.

The present invention provides protease variants, compositions comprising protease variants, and methods of using such protease variants and compositions.

A composition that can activate both a class B and class C G-protein-coupled receptor (GPCR) simultaneously is described herein. This composition can be used in a variety of methods, and is exemplified by a HYBD-HEXA peptide, which is found in SEQ ID NO: 1.

A method for generating binding peptides presented by any given Major Histocompatibility Complex (MHC) protein is presented. The method includes, given a peptide and an MHC protein pair, enabling a Reinforcement Learning (RL) agent to interact with and exploit a peptide mutation environment by repeatedly mutating the peptide and observing an observation score of the peptide, learning to form a mutation policy, via a mutation policy network, to iteratively mutate amino acids of the peptide to obtain desired presentation scores, and generating, based on the desired presentation scores, qualified peptides and binding motifs of MHC Class I proteins.

The invention discloses a disease risk prediction and nutrient recommendation device based on personal genomes. The device comprises a to-be-tested sample personal genome data quality control module, an optimal PRS model construction module, an identification annotation module and a personalized nutrient recommendation module. According to the method, the optimal PRS model adaptive to the East Asian population is constructed. According to the method, an association network is constructed according to a human protein-associated human protein relationship pair, a human protein-compound relationship pair and a food-compound relationship pair, and a GeneRank algorithm is utilized, so that appropriate nutrients are accurately recommended for each individual, and a practical and effective nutrition intervention scheme is provided.

The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FVIII protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FVIII protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of FVIII protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FVIII protein. Such FVIII protein can be expressed for treating disease, e.g., hemophilia A.

Disclosed are protein switches, components of such protein switches, and uses thereof, which can sequester biologically active peptides and / or binding domains, keeping them in an inactive ("off") state until combined with a second, designed polypeptide, termed a key, thereby inducing a conformational change that activates ("on") the biologically active peptide or binding domain.

Described herein are engineered proteins and methods of use of such proteins. Also described herein are complexes, compositions, and systems comprising the engineered proteins of the invention, each of the complexes, compositions, and systems can be used to modify and / or edit a target nucleic acid. The engineered proteins of the invention may be enzymes, and / or may be RNA-guided DNA binding proteins.

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.